News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellular Biomedicine Group (CBMG) To Ring The NASDAQ Stock Market Closing Bell


8/11/2014 7:35:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company") today announced that the Company will ring The NASDAQ Stock Market Closing Bell on Monday, August 18, 2014 at 4:00 P.M. EDT. A live webcast will be available at https://new.livestream.com/nasdaq/live.

"This is a great milestone for CBMG and the biotech industry of China as we are the first pure-play biomedicine company out of China listed on Nasdaq," said Dr. William (Wei) Cao, Chief Executive Officer of the Company. "Ringing the NASDAQ Closing Bell is a symbol of the progress we have made in our business strategy and our commitment to our shareholders. We would like to thank our shareholders, employees and advisors for their support in helping us reach this corporate milestone."

In honor of the occasion, Dr. William (Wei) Cao, Chief Executive Officer and Tony (Bizuo) Liu, Chief Financial Officer, will ring the Closing Bell.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 646 284-9427 vivian.chen@grayling.com

Cellular Biomedicine Group Inc. Logo

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES